AR039957A1 - Derivados de 1-sulfonil-4-aminoalcoxi indol, metodos de preparacion y composicion farmaceutica - Google Patents
Derivados de 1-sulfonil-4-aminoalcoxi indol, metodos de preparacion y composicion farmaceuticaInfo
- Publication number
- AR039957A1 AR039957A1 ARP030101981A ARP030101981A AR039957A1 AR 039957 A1 AR039957 A1 AR 039957A1 AR P030101981 A ARP030101981 A AR P030101981A AR P030101981 A ARP030101981 A AR P030101981A AR 039957 A1 AR039957 A1 AR 039957A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- group
- lower alkyl
- produce
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Se provee, una composición farmacéutica que comprende el compuesto de fórmula 1 y métodos para preparar estos compuestos, y uso de los mismos en la preparación de medicamentos. Estos compuestos son útiles como moduladores del 5-HT6 con los que se pueden tratar enfermedades del SNC y también enfermedades del tracto gastrointestinal. Entre las del primer grupo se pueden mencionar: estados de psicosis, esquizofrenia, trastornos maníaco-depresivos, trastornos de la memoria, y enfermedad de Parkinson y Alzheimer. Reivindicación 1: Un compuesto de la fórmula 1: una sal farmacéuticamente aceptable o una prodroga del mismo caracterizado porque: n es 2 o 3; cada uno de R1 y R2 es independientemente hidrógeno, alquilo inferior, o R1 y R2 junto con el átomo de nitrógeno al cual están unidos pueden formar un grupo heterociclilo; cada R3 es independientemente hidrógeno o alquilo, o R3 y R1 junto con el átomo de nitrógeno al cual R1 está unido puede formar una aprte de anillo de cuatro a siete miembros con R1 y R3 juntos formando un grupo alquileno; R4 es hidrógeno, alquilo inferior, o halaoalquilo; R5 es hidrógeno, alquilo inferior, halo, alcoxi o haloalquilo; y R6 es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido. Reivindicación 18: Un procedimiento para producir un compuesto de fórmula 1 de acuerdo con la reivindicación 1, procedimiento caracterizado porque comprende poner en contacto un compuesto 4-hidroxil-1-sulfonil indol de la fórmula 2, (i) con un compuesto alquilante de la fórmula 3 para obtener un compuesto de fórmula 1; o (ii) (a) con un compuesto ciano de la fórmula: Y-CH2-CN; y (b) reducir el grupo ciano con un agente reductor para producir un compuesto 4-aminoalcoxi-1-sulfonil indol de la fórmula (4); (c) y opcionalmente alquilar el grupo amino con uno o más grupos alquilantes de la fórmula R1-X1 y R2-X2 para producir el compuesto de fórmula (5), en donde R1, R2, R4, R5, R6 y n son aquellos definidos en la reivindicación 1; y cada uno de X1, X2 e Y es independientemente un grupo saliente. Reivindicación 19: Un procedimiento para producir un compuesto de fórmula 1 de acuerdo con la reivindicación 1, caracterizado porque dicho método comprende: (a) poner en contacto un compuesto 4-aminoalcoxi indol de la fórmula (6) con un agente sulfonilante de la fórmula R6-SO2-X para producir el compuesto de fórmula 1 de acuerdo con la reivindicación 1, en donde R1, R2, R3, R4, R5, R6 y n son aquellos definidos en la reivindicación 1; y X es un grupo activante de sulfonilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38604902P | 2002-06-05 | 2002-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039957A1 true AR039957A1 (es) | 2005-03-09 |
Family
ID=29736132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030101981A AR039957A1 (es) | 2002-06-05 | 2003-06-04 | Derivados de 1-sulfonil-4-aminoalcoxi indol, metodos de preparacion y composicion farmaceutica |
Country Status (13)
Country | Link |
---|---|
US (1) | US6774241B2 (es) |
EP (1) | EP1513809A1 (es) |
JP (1) | JP4390698B2 (es) |
KR (1) | KR100657056B1 (es) |
CN (1) | CN1293053C (es) |
AR (1) | AR039957A1 (es) |
AU (1) | AU2003237705B2 (es) |
BR (1) | BR0311593A (es) |
CA (1) | CA2485725A1 (es) |
MX (1) | MXPA04012122A (es) |
PL (1) | PL374401A1 (es) |
RU (1) | RU2323927C2 (es) |
WO (1) | WO2003104193A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
JP2006505559A (ja) * | 2002-10-18 | 2006-02-16 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を持つ4−ピペラジニルベンゼンスルホニルインドール |
KR101157272B1 (ko) | 2003-07-22 | 2012-06-15 | 아레나 파마슈티칼스, 인크. | 5?ht2a 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체 |
SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
JP4975626B2 (ja) | 2004-09-30 | 2012-07-11 | エフ.ホフマン−ラ ロシュ アーゲー | 認知障害の処置用の組成物および方法 |
SI1919896T1 (sl) | 2005-08-12 | 2010-04-30 | Suven Life Sciences Ltd | Aminoaril sulfonamidni derivati kot funkcionalni 5-HT6 ligandi |
US7923566B2 (en) * | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
ES2398299T3 (es) | 2006-07-03 | 2013-03-15 | Proximagen Ltd. | Indoles como moduladores de 5-HT6 |
CN101631787A (zh) * | 2007-03-13 | 2010-01-20 | 比奥维特罗姆上市公司 | 用于肥胖症治疗的三环异喹啉衍生物 |
NZ579766A (en) * | 2007-03-23 | 2012-03-30 | Abbott Gmbh & Co Kg | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
AU2008231787A1 (en) | 2007-03-23 | 2008-10-02 | Abbott Gmbh & Co. Kg | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
NZ583350A (en) | 2007-08-21 | 2012-03-30 | Senomyx Inc | Heteroaryl-hydantoin derivatives as bitter taste inhibitors |
US8076491B2 (en) | 2007-08-21 | 2011-12-13 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
CN102344402B (zh) * | 2010-07-30 | 2015-01-07 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并氮杂环羟乙基胺类化合物、其制备方法和用途 |
US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
WO2016004882A1 (en) | 2014-07-08 | 2016-01-14 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
JP2018520187A (ja) | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1139760A (en) | 1979-03-07 | 1983-01-18 | Makiko Sakai | 1,4-dioxaspiro¬4,5| decene compounds |
JPH04134064A (ja) | 1990-09-25 | 1992-05-07 | Otsuu Kenkyusho | 4―アルコキシインドール誘導体の製造方法 |
WO1995017398A1 (en) | 1993-12-21 | 1995-06-29 | Smithkline Beecham Plc | Indole, indoline and quinoline derivatives with 5ht1d (anti-depressive) activity |
CA2242579A1 (en) | 1996-01-09 | 1997-07-17 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
US5958965A (en) | 1996-08-27 | 1999-09-28 | American Home Products Corporation | 4-aminoethoxy indoles |
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
PL361887A1 (en) * | 2000-10-20 | 2004-10-04 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
NZ525592A (en) * | 2000-11-02 | 2004-07-30 | Wyeth Corp | 1-Aryl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
JP2004517072A (ja) * | 2000-11-24 | 2004-06-10 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Cns障害の治療において有用な化合物 |
TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
MXPA03009476A (es) * | 2001-04-20 | 2004-02-12 | Wyeth Corp | Derivados de heterocicliloxi-,-tioxi-y-aminobenzazol como ligandos de 5-hidroxitriptamina-6. |
MXPA03009490A (es) * | 2001-04-20 | 2004-02-12 | Wyeth Corp | Derivados de heterociclilalcoxi-,-alquiltio-y- alquilaminobenzazol como ligando de 5-hidroxitriptamina-6. |
-
2003
- 2003-05-28 EP EP03735482A patent/EP1513809A1/en not_active Withdrawn
- 2003-05-28 CN CNB038128489A patent/CN1293053C/zh not_active Expired - Fee Related
- 2003-05-28 RU RU2004139050/04A patent/RU2323927C2/ru not_active IP Right Cessation
- 2003-05-28 PL PL03374401A patent/PL374401A1/xx not_active Application Discontinuation
- 2003-05-28 BR BR0311593-3A patent/BR0311593A/pt not_active IP Right Cessation
- 2003-05-28 AU AU2003237705A patent/AU2003237705B2/en not_active Ceased
- 2003-05-28 WO PCT/EP2003/005604 patent/WO2003104193A1/en active Application Filing
- 2003-05-28 JP JP2004511263A patent/JP4390698B2/ja not_active Expired - Fee Related
- 2003-05-28 CA CA002485725A patent/CA2485725A1/en not_active Abandoned
- 2003-05-28 MX MXPA04012122A patent/MXPA04012122A/es active IP Right Grant
- 2003-05-28 KR KR1020047019737A patent/KR100657056B1/ko not_active IP Right Cessation
- 2003-06-04 US US10/454,050 patent/US6774241B2/en not_active Expired - Fee Related
- 2003-06-04 AR ARP030101981A patent/AR039957A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US6774241B2 (en) | 2004-08-10 |
CA2485725A1 (en) | 2003-12-18 |
AU2003237705A1 (en) | 2003-12-22 |
BR0311593A (pt) | 2005-04-26 |
RU2004139050A (ru) | 2005-09-10 |
JP2005533048A (ja) | 2005-11-04 |
MXPA04012122A (es) | 2005-04-19 |
EP1513809A1 (en) | 2005-03-16 |
US20030229069A1 (en) | 2003-12-11 |
CN1659141A (zh) | 2005-08-24 |
KR20050010861A (ko) | 2005-01-28 |
CN1293053C (zh) | 2007-01-03 |
WO2003104193A1 (en) | 2003-12-18 |
RU2323927C2 (ru) | 2008-05-10 |
JP4390698B2 (ja) | 2009-12-24 |
PL374401A1 (en) | 2005-10-17 |
KR100657056B1 (ko) | 2006-12-13 |
AU2003237705B2 (en) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039957A1 (es) | Derivados de 1-sulfonil-4-aminoalcoxi indol, metodos de preparacion y composicion farmaceutica | |
ES2679628T3 (es) | Composiciones novedosas, usos y métodos de su preparación | |
AR059016A4 (es) | Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos. | |
PE20030431A1 (es) | DERIVADOS QUINUCLIDINAS COMO AGONISTAS DEL RECEPTOR NICOTINICO DE LA ACETILCOLINA TIPO a7 | |
AR043466A1 (es) | Proceso de un solo paso para la preparacion de derivados anticonvulsivos | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
AR058728A1 (es) | Derivados de aril-isoxazol-4-il-imidazo[1,5-a]piridina, metodo de preparacion,medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos. | |
PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
UA78999C2 (en) | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 | |
PE20030091A1 (es) | Compuestos arilicos sustituidos con quinuclidinas para el tratamiento de enfermedades | |
PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
UY26020A1 (es) | Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc. | |
AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
ES2837018T3 (es) | Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina | |
AR037906A1 (es) | Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
CA2619897A1 (fr) | Nouveaux derives tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
ES2742078T3 (es) | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa | |
CA3198300A1 (en) | Methods of synthesizing substituted pyridinone-pyridinyl compounds | |
AR034585A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
AR042155A1 (es) | Aminoalcoxiindoles, composicion farmaceutica que los comprenden y usos | |
AR070910A1 (es) | Derivados de sulfonamida sustituida | |
AR056418A1 (es) | Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento | |
ES2290740T3 (es) | Compuestos de n-sulfonilheterociclopirrolilalquilamina como ligandos de 5-hidroxitriptamina-6. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |